Re:Cognition Health is enrolling volunteers to participate in the GAIN study.

This is a clinical trial which provides individuals with Alzheimer’s disease the opportunity to gain early access to a new generation medication, designed to slow, or ideally halt, progression of memory loss and other cognitive symptoms.

The GAIN Trial is a revolutionary new approach to understanding and treating Alzheimer’s Disease, based on the growing scientific evidence of an association between Alzheimer’s and gum disease. Periodontitis is a common, but serious gum infection which causes damage to soft tissue and destroys the bone which supports the teeth, which may cause teeth to become loose or to fall out. Most people are not particularly aware of having had or of having this condition. Scientists have identified a link between the bacteria causing chronic periodontitis and the progression of Alzheimer’s disease. The GAIN study will be trialling a new medication called CO388 to test if this can slow or halt the progression of Alzheimer’s disease by inactivating the toxic proteins, called gingipains, released by the bacteria and stop or slow further damage to healthy brain cells. Patients do not need to have gum disease to participate in this study.

Individuals aged 50-80 years with a diagnosis of Alzheimer’s disease are eligible to participate in this study.

Our team of Brain and Mind Experts at Re:Cognition Health is dedicated to research and are focused on paving the way for a future without Alzheimer’s disease. With every study undertaken we come closer to finding out more about Alzheimer’s disease and finding new treatments.

To register interest to participate in a clinical trial please fill out this form: